Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
C Fernandez, CL van Halsema - HIV/AIDS-Research and Palliative …, 2019 - Taylor & Francis
Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
Cabotegravir plus rilpivirine: first approval
A Markham - Drugs, 2020 - Springer
A regimen comprising extended release injectable suspensions of cabotegravir and
rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV …
rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV …
Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
T Whitfield, A Torkington… - HIV/AIDS-Research and …, 2016 - Taylor & Francis
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis
(PrEP) and treatment of HIV infection. There is a demand for prevention and treatment …
(PrEP) and treatment of HIV infection. There is a demand for prevention and treatment …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
ZW Howe, S Norman, AF Lueken… - … : The Journal of …, 2021 - Wiley Online Library
Abstract Cabotegravir/rilpivirine (CAB/RPV) was recently approved by the US Food and
Drug Administration (FDA) as the first complete parenteral antiretroviral (ART) regimen for …
Drug Administration (FDA) as the first complete parenteral antiretroviral (ART) regimen for …
Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection
R D'Amico, DA Margolis - Current Opinion in HIV and AIDS, 2020 - journals.lww.com
A two-drug intramuscular regimen of cabotegravir and rilpivirine has advanced through
phase 3 clinical development. Results from studies assessing safety, virologic …
phase 3 clinical development. Results from studies assessing safety, virologic …
[PDF][PDF] Long-acting cabotegravir+ rilpivirine for HIV treatment: FLAIR week 96 results
FLAIR WEEK 96 RESULTS Page 1 Conference on Retroviruses and Opportunistic Infections;
March 8–11, 2020; Boston, MA CAB + RPV LA n=283, n (%) DTG/ABC/3TC n=283, n (%) HIV-1 …
March 8–11, 2020; Boston, MA CAB + RPV LA n=283, n (%) DTG/ABC/3TC n=283, n (%) HIV-1 …
Cabotegravir-rilpivirine: The first complete long-acting injectable regimen for the treatment of HIV-1 infection
SH Durham, EB Chahine - Annals of Pharmacotherapy, 2021 - journals.sagepub.com
Objective: To review the efficacy and safety of cabotegravir (CAB) with rilpivirine (RPV) in the
treatment of HIV-1 infection. Data Sources: A literature search was performed using PubMed …
treatment of HIV-1 infection. Data Sources: A literature search was performed using PubMed …
Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 …
GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - academic.oup.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label …
ET Overton, G Richmond, G Rizzardini, H Jaeger… - The Lancet, 2020 - thelancet.com
Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …